Corcept Therapeutics wants to help people who are beyond blue. The biotechnology firm is exploring treatments that regulate the presence of Cortisol, a steroid hormone associated with some psychiatric and metabolic disorders. It is developing its lead candidate Corlux, a version of the compound mifepristone (commonly known as RU-486 or the "abortion pill"), as a means to regulate release patterns of cortisol in patients with psychotic depression, as well as those experiencing weight gain from taking other antipsychotic medications. The company is also investigating whether the drug may treat Cushing's Syndrome, a disorder caused by high levels of cortisol in the blood.